ArticleJAMA oncology2022

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.

Wei Fang Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.